Please Wait a Moment
X

Articles

22Apr

Update on CTS Implementation of the Grifols Procleix Ultrio Elite Assay

22 Apr, 2020 | Return|

In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV, and HCV), performed on the Tigris testing platform, to the newer Ultrio Elite triplex assay, and performed on the Panther testing platform. The CTS Phoenix lab will implement first on July 7th, with the 4 remaining CTS labs located in Charlotte, Dallas, St. Louis amd Tampa all implementing on July 13, 2020.

 

Click here for all the details: Communications

Related

Convalescent Plasma Testing for COVID-19

CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...

Read More >

Seasonal Monitoring for WNV to begin June 1, 2020

Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...

Read More >

Bio-Rad Geenius HIV 1/2 Implementation

CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...

Read More >

October 20th Update on Ortho Conversion

The revised CTS algorithm associated with the Ortho platform is now available for review.  Clie...

Read More >

Update on the Ortho Conversion

At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...

Read More >

Renewed licenses now available on the website

As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....

Read More >